Duvyzat (givinostat) is a novel histone deacetylase (HDAC) inhibitor, mainly used to treat Duchenne muscular dystrophy (DMD). It is suitable for patients aged 6 years and above, regardless of their genetic variation type.
Duvyzat's role
The core mechanism of action of Duvyzat is to regulate gene expression by inhibiting histone deacetylase (HDAC), thereby improving muscle function in DMD patients. Excessive activity of HDAC is closely related to the pathological process of DMD, and the intervention of Duvyzat can slow down muscle degeneration.
Regulating HDAC activity
The main ingredient of Duvyzat, givinostat hydrochloride monohydrate, is an HDAC inhibitor. It selectively inhibits the activity of HDAC and reduces abnormal gene expression, thereby improving the regenerative capacity of muscle cells. This mechanism plays a key role in slowing down muscle fibrosis and inflammatory response in DMD patients.
Improving muscle function
Clinical studies have shown that Duvyzat can significantly delay the degeneration of muscle function in DMD patients. By regulating HDAC, it promotes the repair and regeneration of muscle cells, helping patients maintain exercise capacity for longer. This effect is of great significance for improving the quality of life of patients.
The mechanism of action of Duvyzat provides a new direction for the treatment of DMD. Its high selectivity and specificity make it the only non-steroidal drug currently applicable to all types of DMD genetic variations.
Efficacy of Duvyzat
Duvyzat has shown significant efficacy in the treatment of DMD, especially in delaying disease progression and improving patient symptoms. Its clinical value has been verified by multiple studies.
Delaying disease progression
Duvyzat effectively slows down the rate of muscle degeneration in DMD patients by inhibiting HDAC activity. Clinical trials have shown that patients receiving treatment show a slower decline in muscle strength and motor function, and some patients even achieve symptom stabilization.
Wide applicability
Unlike other DMD therapies, Duvyzat is suitable for patients with all genetic variation types. This feature makes it an important choice in the treatment of DMD, especially for those patients who cannot use other therapies due to special gene mutation types.
The efficacy of Duvyzat is not only reflected in delaying disease progression, but also in its wide applicability, which brings hope to more DMD patients.
Duvyzat medication precautions
Although Duvyzat has performed well in the treatment of DMD, it is still necessary to pay attention to a number of matters during its use to ensure patient safety and maximize the treatment effect.
Monitoring blood and lipid levels
Before and during treatment, patients' platelet counts and serum triglyceride levels should be monitored regularly. If the platelet count is less than 150×10⁹/L or the triglyceride level continues to rise, the dose may need to be adjusted or treatment may be suspended.
Adverse reaction management
Duvyzat may cause adverse reactions such as diarrhea, nausea, and thrombocytopenia. For moderate or severe adverse reactions, the dose should be adjusted according to the patient's weight and the drug should be discontinued if necessary. At the same time, the electrocardiogram should be closely monitored to prevent the risk of arrhythmias caused by prolonged QT interval.
Duvyzat medication precautions cover all aspects from the start of treatment to long-term management. Reasonable monitoring and adjustment are the key to clarify the treatment effect.
